All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

How do MM cells develop resistance to BCMA-targeted agents? Can it be overcome in the clinic?

During the EHA2021 Virtual Congress, the Multiple Myeloma Hub spoke with Leo Rasche, University Hospital of Würzburg, Würzburg, DE. We asked, How do multiple myeloma cells develop resistance to B-cell maturation antigen (BCMA)-targeted agents? Can it be overcome in the clinic?

In this video,  Rasche discusses the recent discovery of a resistance mechanism to anti-BCMA therapies, which include both bispecific antibodies and chimeric antigen receptor T-cell therapies.

For more information about BCMA-resistance mechanisms, read our latest review here.

 

Share: